BPC-157 Certificate of Analysis: HPLC and MS Interpretation in Australia

What must a BPC-157 CoA list before HPLC and MS can be interpreted?

A CoA is only interpretable when the chemical entity, the lot, and the methods are named with enough specificity that a second laboratory could repeat the measurements. For BPC-157, that starts with identification of a fifteen-residue peptide. Reviews refer to the compound as a gastric pentadecapeptide, which fixes the residue count that identity tests must support (PMID:17186181; PMID:29998800). The CoA should state the sequence or sequence code, the theoretical mass, the salt form (commonly trifluoroacetate or acetate), and the appearance (typically a lyophilised solid).

Batch metadata belong beside the chemistry: lot number, catalogue code, quantity represented, date of synthesis or packing, date of analysis, and the testing laboratory’s name. The lot on the CoA must match the vial label and the packing list used for Australian tracked dispatch. A mismatch makes later HPLC or MS interpretation unusable because the chromatogram cannot be tied to the material on the bench.

Method identification is the third block. HPLC interpretation requires column chemistry, mobile-phase modifiers, detection wavelength, gradient or isocratic programme, integration parameters, and system-suitability outcome. MS interpretation requires ionisation mode, analyser type, observed m/z with charge state, and the acceptance window in daltons or parts per million.

The CoA should separate specification limits from measured results. A purity figure is not self-explanatory unless the document states whether it is HPLC area-percent at a named wavelength, a diode-array peak-purity index, or an MS-based related-substance estimate. Net peptide content, water and residual counter-ion, when reported, should be independent line items.

How should HPLC purity be read on a BPC-157 certificate of analysis in Australia?

Reversed-phase HPLC is the purity method most often attached to a BPC-157 CoA. Interpretation begins with detection wavelength and the integration report, not the headline percentage. The pentadecapeptide sequence used in the literature contains no tryptophan, tyrosine or phenylalanine, so absorbance at 280 nm is not a meaningful purity channel; laboratories typically record 210–220 nm, where peptide-bond absorbance dominates. A CoA that quotes purity at 280 nm for this sequence is methodologically mismatched.

Area-percent purity is the main-peak area divided by the sum of integrated peak areas above a stated threshold, at a stated wavelength, under a stated gradient. It is not a weight-percent assay of the lyophilised solid. Residual water, counter-ion and non-chromophoric material can make the mass of peptide-related substance differ from HPLC area-percent. When a CoA reports both HPLC purity and net peptide content, those figures must not be averaged.

Related-substance reading requires the chromatogram. Analysts should confirm a dominant peak with documented retention time, resolution from the nearest impurity, and the absence of unlabelled shoulders. Shoulders may indicate proline conformational isomers; early polar peaks may indicate truncation or aspartimide-related species at aspartic acid residues. If the CoA omits the chromatogram, the percentage cannot be audited.

Diode-array peak-purity indices are not a substitute for chromatographic purity. A favourable purity angle or match factor indicates spectral homogeneity, not the absence of co-eluting peptides with similar ultraviolet spectra. For a non-aromatic pentadecapeptide the ratiogram is less informative than for tryptophan-containing sequences. System-suitability results (plates, tailing, replicate precision), when listed, show whether the method was in control.

How is mass-spectrometric identity confirmed on a BPC-157 CoA?

Electrospray ionisation mass spectrometry is the identity method that should sit beside HPLC on a BPC-157 certificate of analysis. Literature describes the compound as a gastric pentadecapeptide, implying a fifteen-residue chain with a monoisotopic mass near 1418.7 Da and an average mass near 1419.5 Da for the free peptide (PMID:31158953; PMID:39204186). A CoA that reports only a rounded molecular weight without charge-state assignment is incomplete.

Typical ESI spectra show a doubly protonated ion near m/z 710.4 and a singly protonated ion near m/z 1419.7, plus sodium or potassium adducts. Interpretation should confirm that observed m/z matches theory within the stated window, that charge state is explicit, that the isotope pattern fits a C62-scale peptide, and that no unexplained base peak of comparable intensity is present. Pass/fail identity without m/z values cannot be checked.

Related masses belong in the purity discussion. A +18 Da species may indicate hydration; −18 Da may indicate dehydration or aspartimide; deletion sequences appear as residue-mass losses. The sequence contains no methionine, so a +16 Da peak should not be assumed to be methionine sulfoxide. Isobaric co-elution can be visible in MS across the HPLC peak even when area-percent looks clean.

Tandem MS upgrades identity from correct mass to sequence evidence. b- and y-ion coverage through the proline-rich region is stronger than intact mass alone. Australian CoAs should name the analyser class, because a 0.5 Da quadrupole window is not equivalent to a few-ppm high-resolution window.

Which lot-traceability fields can Australian laboratories audit against the vial?

In Australia, a BPC-157 certificate of analysis is a laboratory quality document, not a therapeutic-goods dossier. Receiving laboratories should still audit how the vial on the shelf maps to the chromatogram in the file. That mapping is lot traceability: every analytical result is meaningless unless it is locked to a batch identifier that also appears on the primary container, the secondary label, the dispatch note and the archive copy of the CoA.

The minimum auditable set is lot or batch number, unique CoA document number or revision, test dates, testing-site identity, method codes for HPLC and MS, and the specification used for pass/fail. Where a supplier issues a batch report as well as a one-page CoA, the chromatogram, mass spectrum, integration table and system-suitability summary should share the same lot number. Multi-vial orders drawn from one lot should carry one CoA; if vials show different lots, each lot needs its own certificate.

Catalogue numbers and chemical names must be consistent with the pentadecapeptide described in the scientific literature (PMID:36200148; PMID:35203478). If the CoA uses a proprietary code, the sequence should still appear so the receiving laboratory can confirm the fifteen-residue entity. Nomenclature drift—BPC157, BPC 157 and historical codes such as PL 14736—should be cross-referenced, not treated as different substances without evidence (PMID:17186181).

Fulfilment documentation should emphasise local Australian stock, tracked dispatch and the batch paperwork that travels with the parcel. A tracking number that is not linked to a lot number does not complete the audit trail. Laboratories should file the dispatch record with the CoA under the same lot.

How should HPLC area-percent and MS-related substances be reconciled?

HPLC area-percent and MS identity are complementary; they are not interchangeable. A lot can show a high HPLC main-peak percentage and still fail a strict mass check if the main peak is a co-eluting mixture. A clean intact-mass spectrum of a collected fraction does not prove the bulk solid is free of UV-active impurities that never entered the mass spectrometer. A BPC-157 CoA therefore requires both traces and a statement of how each was generated.

Reconcile in order. Confirm HPLC and MS belong to the same lot and, preferably, that LC–MS was a coupled run. Assign the main-peak MS envelope to the theoretical pentadecapeptide ions. List every HPLC impurity above the reporting threshold and ask whether MS assigned a mass; unassigned peaks are documentation gaps. List MS-related masses above a defined intensity and ask whether each has an HPLC peak. Species that ionise well but absorb poorly at 214 nm can be under-represented in area-percent.

Counter-ion and water complete mass balance. Trifluoroacetate or acetate, measured by ion chromatography or 19F NMR for TFA, is mass that HPLC area-percent ignores. Karl Fischer water likewise sits outside the peptide-related HPLC sum. Net peptide content should be reconcilable with HPLC peptide-related purity after water, counter-ion and residual solvent are subtracted. Reporting 99% HPLC purity and 99% net content without residual data is inconsistent unless those residuals were shown to be negligible.

Acceptance criteria must stay method-specific: area-percent at a named wavelength and threshold; MS identity as a mass window; peak purity as a software angle and threshold.

What CoA red flags should researchers check before buying BPC-157 in Australia?

Before a research purchase proceeds, the CoA should be read as a rejectable specification. The following gaps are material for BPC-157 HPLC and MS interpretation in Australia.

Missing raw data: a purity percentage without a chromatogram, or identity stated only as 'confirmed', cannot be interpreted. Require the HPLC integration report and the mass spectrum in the same lot file. Screenshots without axes or m/z scales cannot be re-read against a reporting threshold.

Method opacity: if the CoA does not name HPLC column class, wavelength, modifier and gradient, lots with identical printed purity are not comparable. If MS omits ionisation mode, analyser class and mass window, the identity test is undefined.

Lot mismatch: vial labels, invoices, CoAs and batch reports that disagree on lot number cannot be filed as one record. Multi-vial shipments should share one lot and one CoA or present a CoA per lot. Local stock and tracked dispatch help only when tracking cites the same lot as the certificate.

Sequence omission: the CoA must identify the pentadecapeptide. Literature that names BPC-157 as a gastric pentadecapeptide supplies residue count; it does not replace lot-specific sequence or accurate mass (PMID:30915550; PMID:34267654).

Collapsed purity: HPLC area-percent, water, counter-ion and net peptide content must be separate lines. Absent system suitability, truncated chromatograms, missing related-substance tables, and generic PDFs reused across lots are further reject criteria. These checks establish only whether identity and purity have been documented for a research reagent.

Order Bpc 157 with documentation

If this guide helped you evaluate Bpc 157 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.

Open the Bpc 157 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.

Frequently asked questions

What does a BPC-157 certificate of analysis document for research use?

It records lot identity and purity for a research reagent: HPLC area-percent at a named wavelength, MS m/z with charge state, method identifiers, and batch numbers that must match the vial. It is not a therapeutic-goods file and does not imply suitability for any biomedical use. Australian laboratories should archive it with tracked-dispatch records.

Why is 280 nm the wrong HPLC channel for BPC-157 purity?

The pentadecapeptide sequence contains no tryptophan, tyrosine or phenylalanine, so 280 nm absorbance is negligible. CoA purity should be generated at about 210–220 nm, where peptide-bond absorbance is measured. A 280 nm purity figure is not comparable to a 214 nm figure for this analyte.

Which mass-spectrometric signals support BPC-157 identity on a CoA?

ESI typically shows [M+2H]2+ near m/z 710.4 and [M+H]+ near m/z 1419.7 for the free pentadecapeptide (monoisotopic mass about 1418.7 Da). The CoA should report observed m/z, charge state and the mass window. Tandem MS b- and y-ions, when attached, support sequence-level identity beyond intact mass.

How should net peptide content be read beside HPLC purity?

HPLC area-percent is a relative chromatographic ratio. Net peptide content reflects the mass fraction of peptide after water, counter-ion and solvents. The two results answer different questions and must not be treated as duplicates. A CoA that reports both without water or counter-ion data cannot be mass-balanced.

What lot fields should match before an Australian laboratory accepts a BPC-157 shipment?

Lot number on the vial, CoA, batch report and dispatch note should be identical. Local stock and tracked dispatch complete the trail only when the tracking record cites that same lot. Mismatched lots require separate certificates; a generic PDF without a lot number is not a release document.

Can literature on the gastric pentadecapeptide replace lot HPLC and MS?

No. Peer-reviewed papers identify BPC-157 as a fifteen-residue gastric pentadecapeptide and thereby set expected residue count and mass, but they do not characterise a supplier’s batch. Only lot-specific HPLC chromatograms and MS spectra on the certificate of analysis document the vial in hand.

References

1. PMID:30915550 — Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell Tissue Res — 2019
2. PMID:34267654 — Stable Gastric Pentadecapeptide BPC 157 and Wound Healing — Front Pharmacol — 2021
3. PMID:17186181 — Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response — Inflammopharmacology — 2006
4. PMID:29998800 — BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Curr Pharm Des — 2018
5. PMID:31158953 — Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future — Gut Liver — 2020
6. PMID:39204186 — Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review — Pharmaceuticals (Basel) — 2024
7. PMID:36200148 — Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways — Curr Med Chem — 2023
8. PMID:35203478 — Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats — Biomedicines — 2022

Research use only

This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.